Close menu




November 25th, 2020 | 11:44 CET

Sartorius, Drägerwerk, Desert Gold: Vaccines for the portfolio

  • Investments
Photo credits: pixabay.com

The crisis is on the home stretch. Several vaccines have been found and are about to be approved. But it will still take a while before the pandemic is defeated: millions of people need to be vaccinated. Usually, two doses of vaccine are required for this purpose, which must be administered at specific intervals. This Herculean logistical task must succeed in many countries if normality is to be restored. This much seems inevitable: 2021 will still be under the influence of the virus. Corona also leaves its mark on the capital market, whether directly or indirectly.

time to read: 4 minutes | Author: Nico Popp
ISIN: CA25039N4084 , DE0007165631 , DE0005550602

Table of contents:


    More than ventilators: Drägerwerk

    When the pandemic first struck in March 2020, Drägerwerk shares were quickly considered winners of the crisis. Drägerwerk produces protective masks and also respiratory equipment. At the beginning of the crisis, the latter, in particular, was considered a panacea - if you are ventilated, you can cure the virus and will be healthy afterwards. However, consequential damage caused by ventilation and the high mortality rate in older ventilation patients soon ensured that the focus is placed on preventing infections. At Drägerwerk, order intake nevertheless climbed by around 75% in the first half of 2020. Some orders, such as the agreement to supply FFP3 masks to the UK, even extend into 2021.

    On the stock market, not much has remained of the profits from the first weeks of the pandemic. On a one-year horizon, the Drägerwerk share is still up 18 percent. But that is better than nothing. The long-term performance of the share price shows that the share was not doing so well even before the pandemic - on a three-year horizon, the value is negative - despite the pandemic profits. In view of the impending mass vaccinations, which may have to be repeated for years, the Drägerwerk share remains a solid choice. However, investors should no longer expect significant jumps.

    Sartorius as best pandemic standard

    Things look a little different at Sartorius. The Göttingen-based Company specializes in disposables for laboratories. Whenever drugs or vaccines are manufactured, products from Sartorius can be used. Since vaccines will be produced in the coming months without spilling, the prospects for Sartorius are incredibly positive. For 2020, the Company expects an increase in sales revenue of up to 26%. Best of all, this trend is likely to continue in 2021. Only then will the production of vaccines be ramped up further. At the same time, the motto "test, test, test" applies - here, too, Sartorius will benefit.

    The share is already highly valued at present. In one year, the value has risen by more than one hundred percent. When a share price increases like clockwork, investors can sit back and relax, and, should stick with it. Sartorius is one of the best shares in the standard corona range. The good news is that the Company is well-positioned, even independent of the pandemic, and is anything but crisis-prone.

    Desert Gold offers substance and a lever on the gold price

    While states are pumping more and more money into the fight against the pandemic and its consequences, debt ratios, are climbing worldwide. Central banks are already standing by to support the starving economy - many industries are facing the end of the crisis. In the years 2008 to 2011, billions also flowed into rescue packages and emergency loans. At that time, the banking and euro crisis ensured that the price of gold rose rapidly and reached a new all-time high. This summer, the gold price reached this all-time high. Before that, a lot of speculative capital flowed into the gold market. The trend was recently reversed in the wake of better news on the economy and research laboratories.

    Here could be an opportunity for investors who are not only thinking of healthcare stocks. Just as the pandemic will keep us busy for many months to come, the economy will continue to be on the drip from governments and central banks, and this should be a driver for the gold price. Companies such as the small Canadian Company Desert Gold could benefit.

    Desert Gold operates in Mali, the fourth-largest gold producer in Africa. Although more than 26 million ounces of gold have already been proven as reserves in the country, the exploration potential is considered to be large. Although exploration is the field of activity of smaller companies, such as Desert Gold, large companies such as Barrick Gold, B2Gold, or Endeavour have already positioned themselves in Mali. Most recently, Kinross Gold also announced that it intends to sell projects in America in order to position itself in West Africa and Russia. Desert Gold has a property in the middle of a historic mining region and has already reported promising drill results. These include approximately 6.3 g/t over a distance of 13 metres.

    The highest returns are seen off the beaten track

    During the summer, the share was considered the insider tip and tripled in value within a few months. In the meantime, the value of the share has fallen significantly again. The reason is probably sales by speculative investors. If gold should end its consolidation and the market's focus should become more on economic uncertainty or rising inflation again, Desert Gold should quickly get back on track - after all, work is continuing, and the project is considered promising. Whether laboratory equipment, protective masks or the world's oldest independent currency - investors should position themselves where there is demand. The highest returns are sometimes achieved by investors who are looking for opportunities off the beaten track.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET

    Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power

    • Digitization
    • Commodities
    • Investments

    The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Stefan Feulner on November 29th, 2022 | 13:32 CET

    Nvidia, Meta Materials, SFC Energy - Strong signs

    • Technology
    • Investments
    • nanotechnology

    After turbulent months on the technology stock markets with high markdowns, a bottoming out is taking place across the board. While many companies are reporting better-than-expected figures, investors are also buying oversold companies whose quarterly figures were below analysts' consensus. Due to the still high fluctuation range, high trading profits can be expected.

    Read